CGIM
COGT icon

Cannon Global Investment Management’s Cogent Biosciences COGT Stock Holding History

Cannon Global Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,800
Closed -$121K – 60
2021
Q1 		$121K Buy
+13,800
New +$133K 0.21% 87

Other funds holding COGT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Cannon Global Investment Management's COGT Position: Q2 2021 in Review

Cannon Global Investment Management sold out of Cogent Biosciences (COGT) in Q2 2021, closing a stake of 13,800 shares — an estimated $121K sold.

Cannon Global Investment Management first reported a position in COGT in Q1 2021 and held it in 1 quarter. The position peaked at $121K in Q1 2021. 69 funds tracked by Wall St. Rank hold COGT as of Q2 2021.

  • Cannon Global Investment Management reported no remaining Cogent Biosciences position as of Q2 2021 after selling out during the quarter.
  • Cannon Global Investment Management sold 13,800 Cogent Biosciences shares in Q2 2021, an estimated $121K.
  • Cannon Global Investment Management first reported a position in Cogent Biosciences in Q1 2021 and held it in 1 quarter.
  • Cannon Global Investment Management's Cogent Biosciences position peaked at $121K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2021.

Based on Cannon Global Investment Management's 13F filing for Q2 2021, filed 3 Aug 2021.